See more : McMillan Shakespeare Limited (MMS.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Yield10 Bioscience, Inc. (YTEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Yield10 Bioscience, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
You may be interested
- PT Bintang Mitra Semestaraya Tbk (BMSR.JK) Income Statement Analysis – Financial Results
- MA Financial Group Limited (MAF.AX) Income Statement Analysis – Financial Results
- Comer Industries S.p.A. (COM.MI) Income Statement Analysis – Financial Results
- Smaregi, Inc. (4431.T) Income Statement Analysis – Financial Results
- Citizens Financial Services, Inc. (CZFS) Income Statement Analysis – Financial Results
Yield10 Bioscience, Inc. (YTEN)
About Yield10 Bioscience, Inc.
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. The company, through its Trait Factory, a trait gene discovery platform develops enhanced oilseed Camelina sativa for the production of proprietary seed products; and discovers high value genetic traits for the agriculture and food industries. Yield10 Bioscience, Inc. has license agreements with GDM Seeds; J. R. Simplot; Forage Genetics International, LLC; and Bayer AG. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporate in 1992 and is headquartered in Woburn, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.00K | 450.00K | 614.00K | 799.00K | 806.00K | 556.00K | 944.00K | 1.16M | 2.59M | 2.80M | 5.39M | 42.32M | 1.43M | 448.00K | 1.43M | 1.56M | 1.68M | 4.59M | 2.78M | 3.68M | 2.38M | 1.99M |
| Cost of Revenue | 290.00K | 656.00K | 578.00K | 5.22M | 4.85M | 4.78M | 4.60M | 5.67M | 660.00K | 1.48M | 3.03M | 1.43M | 24.45M | 23.67M | 24.47M | 24.67M | 19.90M | 11.24M | 5.98M | 5.43M | 0.00 | 0.00 |
| Gross Profit | -230.00K | -206.00K | 36.00K | -4.42M | -4.04M | -4.23M | -3.65M | -4.51M | 1.93M | 1.32M | 2.37M | 40.89M | -23.02M | -23.23M | -23.05M | -23.11M | -18.22M | -6.65M | -3.20M | -1.75M | 2.38M | 1.99M |
| Gross Profit Ratio | -383.33% | -45.78% | 5.86% | -553.32% | -501.49% | -760.25% | -386.97% | -389.21% | 74.56% | 47.07% | 43.90% | 96.63% | -1,615.44% | -5,184.15% | -1,617.26% | -1,486.30% | -1,082.47% | -144.77% | -115.04% | -47.53% | 100.00% | 100.00% |
| Research & Development | 8.32M | 7.75M | 6.20M | 5.36M | 4.85M | 4.78M | 4.60M | 5.67M | 16.57M | 17.34M | 19.13M | 23.18M | 0.00 | 0.00 | 0.00 | 24.67M | 19.90M | 11.24M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.15M | 6.15M | 6.11M | 5.05M | 4.55M | 5.09M | 5.63M | 5.74M | 9.11M | 10.81M | 13.74M | 14.11M | 15.84M | 15.71M | 15.68M | 15.78M | 15.60M | 10.88M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.15M | 6.15M | 6.11M | 5.05M | 4.55M | 5.09M | 5.63M | 5.74M | 9.11M | 10.81M | 13.74M | 14.11M | 15.84M | 15.71M | 15.68M | 15.78M | 15.60M | 10.88M | 3.83M | 3.25M | 0.00 | 2.64M |
| Other Expenses | 0.00 | 41.00K | -3.00K | 83.00K | 21.00K | 134.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.48M | 13.90M | 12.31M | 10.41M | 9.40M | 9.88M | 10.23M | 11.41M | 25.68M | 28.15M | 32.87M | 37.29M | 15.84M | 15.71M | 15.68M | 40.45M | 35.50M | 22.11M | 3.83M | 3.25M | 0.00 | 7.05M |
| Cost & Expenses | 14.48M | 13.90M | 12.31M | 10.41M | 9.40M | 9.88M | 10.23M | 11.41M | 26.34M | 29.63M | 35.90M | 38.71M | 40.29M | 39.39M | 40.15M | 40.45M | 35.50M | 22.11M | 9.81M | 8.68M | 0.00 | 7.05M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 96.00K | 158.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.00K | 0.00 | 0.00 | 0.00 | 5.94M | 1.47M | 109.36K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 13.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -80.00K | 0.00 | 772.00K | 2.89M | 0.00 | 5.00K | 10.14K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 290.00K | 656.00K | 578.00K | 611.00K | 1.83M | 784.00K | 206.00K | 177.00K | 265.00K | 507.00K | 928.00K | 1.30M | 1.51M | 1.65M | 2.73M | 3.73M | 1.45M | 964.00K | 314.57K | 265.25K | 0.00 | 0.00 |
| EBITDA | -14.13M | -13.19M | -11.47M | -9.43M | -8.39M | -9.12M | -9.08M | -10.07M | -12.35M | -26.32M | -27.61M | 4.90M | -37.35M | -37.29M | -36.00M | -35.16M | -32.37M | -16.56M | -6.71M | -4.73M | 2.38M | -5.06M |
| EBITDA Ratio | -23,545.00% | -2,930.67% | -1,982.41% | -1,101.75% | -609.93% | -1,640.83% | -949.58% | -836.50% | -907.48% | -942.25% | -547.26% | 11.58% | -2,621.33% | -8,324.11% | -2,525.96% | -2,261.16% | -1,923.05% | -360.78% | -216.11% | -128.73% | 100.00% | -254.60% |
| Operating Income | -14.42M | -13.45M | -11.69M | -9.61M | -8.60M | -9.32M | -9.28M | -10.25M | -23.74M | -26.83M | -30.50M | 3.60M | -38.86M | -38.94M | -38.73M | -38.89M | -33.82M | -17.52M | -7.02M | -5.00M | 2.38M | -5.06M |
| Operating Income Ratio | -24,028.33% | -2,989.11% | -1,904.23% | -1,202.63% | -1,066.50% | -1,676.08% | -983.37% | -884.21% | -915.30% | -958.18% | -565.48% | 8.51% | -2,727.09% | -8,691.74% | -2,717.82% | -2,501.09% | -2,009.27% | -381.79% | -252.59% | -135.94% | 100.00% | -254.60% |
| Total Other Income/Expenses | -38.00K | 41.00K | 697.00K | -541.00K | -4.61M | 134.00K | -113.00K | -38.00K | 29.00K | 61.00K | -4.00K | 27.00K | 76.00K | 136.00K | 0.00 | 0.00 | 5.94M | 1.46M | -699.64K | 0.00 | -2.38M | 5.06M |
| Income Before Tax | -14.46M | -13.41M | -11.00M | -10.15M | -13.21M | -9.19M | -9.40M | -10.29M | -23.68M | -26.77M | -30.51M | 3.63M | -38.79M | -38.80M | 0.00 | 0.00 | -27.88M | -16.06M | -7.72M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -24,091.67% | -2,980.00% | -1,790.72% | -1,270.34% | -1,638.96% | -1,651.98% | -995.34% | -887.49% | -912.91% | -956.00% | -565.55% | 8.58% | -2,721.75% | -8,661.38% | 0.00% | 0.00% | -1,656.27% | -349.93% | -277.76% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 156.00K | 36.00K | 56.00K | -254.00K | 104.00K | 113.00K | -1.10M | -62.00K | 2.71M | 4.00K | 0.00 | 0.00 | 0.00 | -772.00K | -2.89M | 0.00 | 0.00 | 600.79K | 54.31K | 6.64M | 5.19M |
| Net Income | -14.46M | -13.57M | -11.03M | -10.21M | -12.96M | -9.19M | -9.40M | -7.60M | -23.68M | -29.53M | -30.51M | 3.63M | -38.79M | -38.80M | -37.96M | -36.01M | -27.88M | -16.06M | -7.63M | -5.05M | -6.64M | -5.19M |
| Net Income Ratio | -24,091.67% | -3,014.67% | -1,796.58% | -1,277.35% | -1,607.44% | -1,651.98% | -995.34% | -656.08% | -912.91% | -1,054.79% | -565.55% | 8.58% | -2,721.75% | -8,661.38% | -2,663.65% | -2,315.43% | -1,656.27% | -349.93% | -274.20% | -137.42% | -278.62% | -260.83% |
| EPS | -43.66 | -66.25 | -55.95 | -103.21 | -851.98 | -887.78 | -2.77K | -2.65K | -9.18K | -27.97K | -51.50K | 277.48 | -72.21K | -84.34K | -94.26K | -91.74K | -73.75K | -172.10K | -149.23K | -79.89K | -158.62K | -100.88K |
| EPS Diluted | -43.66 | -66.25 | -55.95 | -103.21 | -851.98 | -887.78 | -2.77K | -2.65K | -9.18K | -27.97K | -51.50K | 277.48 | -72.21K | -84.34K | -94.26K | -91.74K | -73.75K | -172.10K | -121.96K | -79.89K | -158.62K | -100.88K |
| Weighted Avg Shares Out | 331.10K | 204.77K | 197.16K | 98.89K | 15.21K | 10.35K | 3.39K | 2.87K | 2.58K | 1.06K | 592.33 | 588.00 | 537.10 | 460.06 | 402.69 | 392.46 | 377.99 | 93.33 | 51.10 | 63.27 | 41.86 | 51.43 |
| Weighted Avg Shares Out (Dil) | 331.10K | 204.77K | 197.16K | 98.89K | 15.21K | 10.35K | 3.39K | 2.87K | 2.58K | 1.06K | 592.33 | 589.07 | 537.10 | 460.06 | 402.69 | 392.46 | 377.99 | 93.33 | 62.52 | 63.27 | 41.86 | 51.43 |
Metabolix, Inc. (YTEN) Reports Q1 Loss, Misses Revenue Estimates
Metabolix, Inc. (YTEN) delivered earnings and revenue surprises of -3.03% and 10.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Yield10 Bioscience to Announce First Quarter 2022 Financial Results and Host a Conference Call on Wednesday, May 11, 2022
WOBURN, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its first quarter 2022 financial results and provide a corporate update on Wednesday,...
Should You Buy Wheat Stocks? 3 Companies To Consider.
Surging wheat prices could provide systemic support to many commodity stocks that have U.S. exposure. Here are three wheat stocks to buy.
Yield10 Bioscience to Present at the Maxim Group 2022 Virtual Growth Conference and Participate in Fireside Chat
WOBURN, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that President and CEO Oliver Peoples, Ph.D. will participate at the Maxim Group 2022 Virtual Growth Conference, which is...
Yield10 Bioscience Chief Executive Officer Dr. Oliver Peoples to Present on Development of Camelina Crop for Use in Biofuels at ABLC 2022 Conference
-Establishing the Camelina crop as a replenishable reserve of feedstock oil for biofuels
Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q4 2021 Results - Earnings Call Transcript
Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q4 2021 Results - Earnings Call Transcript
Yield10 Bioscience to Announce Fourth Quarter and Full Year 2021 Financial Results and Host a Conference Call on Wednesday, March 9, 2022
WOBURN, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2021 financial results and provide a corporate...
Yield10 Bioscience to Present at the H.C. Wainwright Bioconnect Virtual Conference
WOBURN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, announced today that President and CEO Oliver Peoples, Ph.D. will give a corporate presentation at the H.C. Wainwright Bioconnect Investment Conference, which is...
Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present on Advances in Utilizing CRISPR Genome Editing to Increase Seed Oil Content in Camelina at Canola Week Conference
WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will present during the Canola Week 2021 Conference taking place in virtual format November...
Yield10 Bioscience, Inc. (YTEN) CEO Ollie Peoples on Q3 2021 Results - Earnings Call Transcript
Yield10 Bioscience, Inc. (YTEN) CEO Ollie Peoples on Q3 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports